Off-label promotion is when a drug or medical device manufacturer markets its product for a use, dose, or patient group that the FDA never approved, and it is generally illegal under federal law. The prohibition targets the company, not the prescriber. A doctor can legally prescribe an approved drug for an unapproved purpose whenever they think it fits the patient. A manufacturer that pushes that same unapproved use through sales reps, sponsored talks, or promotional materials is a different story, and that is where the enforcement cases live.
What Off-Label Promotion Looks Like in Practice
The FDA approves each drug and device for specific uses, doses, and patient populations. Anything the manufacturer does to encourage use outside those boundaries counts as off-label promotion. It can take many shapes: a sales representative telling a doctor the drug works for a condition not on the label, a company-funded lecture series that highlights unapproved uses, ghostwritten journal articles that steer physicians toward off-label prescribing, or consumer advertising that hints at broader effectiveness than the label supports.
The line between education and promotion can blur. A company might sponsor a continuing-education event where a paid physician discusses research on an unapproved use. On the surface it looks like science. When the sponsor picks the speaker, sets the topic, and targets an audience of likely prescribers, regulators tend to treat it as marketing wearing a lab coat.
Why Doctors Can Prescribe Off-Label but Companies Can’t Promote It
Once a drug is approved, your doctor can prescribe it for any condition they judge medically appropriate. The FDA has said so directly: healthcare providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.”1U.S. Food and Drug Administration. Understanding Unapproved Use of Approved Drugs Off Label Federal law reinforces that authority.
Off-label prescribing is not fringe. Studies estimate that roughly one in four to one in three prescriptions in the United States are off-label. In pediatrics the share is much higher, because many drugs are never formally tested in children. Oncologists routinely use approved cancer drugs for tumor types not listed on the label when the clinical evidence supports it.
The regulatory worry is not that unapproved uses are automatically dangerous. It is that they have not been through the same rigorous review for safety and effectiveness. When a manufacturer promotes an unapproved use, it is essentially making marketing claims the FDA never vetted, and prescribers and patients may rely on those claims without seeing how thin the evidence behind them is.
The Federal Laws That Make It Illegal
Off-label promotion cases usually rest on three overlapping federal statutes, and prosecutors often invoke all three in the same case.
Misbranding Under the Federal Food, Drug, and Cosmetic Act
The FDCA makes it illegal to introduce a “misbranded” drug or device into interstate commerce.2Office of the Law Revision Counsel. 21 USC 331 – Prohibited Acts A drug counts as misbranded when its labeling is false or misleading, or when it lacks adequate directions for its intended use.3Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices Here is the pivot: when a company promotes a drug for an unapproved use, that promotion can establish a new “intended use” for the product. The labeling does not include directions for that new intended use, so the drug becomes misbranded by definition. Nothing about the drug itself has changed. The promotion alone creates the violation, and the FDCA authorizes criminal penalties for it.4Office of the Law Revision Counsel. 21 USC 333 – Penalties
The False Claims Act
The False Claims Act is where the real financial exposure lives. When a company promotes a drug off-label and doctors write prescriptions for that use, Medicare and Medicaid may end up paying for prescriptions they would not have covered. The government treats those reimbursement claims as fraudulent. The FCA imposes liability for three times the government’s damages plus a per-claim penalty.5U.S. Department of Justice. The False Claims Act A nationwide promotional campaign can generate millions of individual prescriptions, and the math scales accordingly.
The Anti-Kickback Statute
Off-label promotion often travels with payments to physicians: speaking fees for promotional talks, consulting fees for advisory boards that are really marketing exercises, meals, travel. When the actual purpose is to reward or encourage prescribing rather than to compensate genuine professional work, the payments violate the federal Anti-Kickback Statute. A kickback violation can then feed a False Claims Act case, because a prescription tainted by an illegal kickback is treated as a false claim once submitted to a federal healthcare program.
The First Amendment Complication
The picture changed in 2012 when the Second Circuit decided United States v. Caronia. The court held that “the government cannot prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDA-approved drug.”6Justia Law. United States v Caronia, No 09-5006 (2d Cir 2012) Three years later, a federal district court extended the reasoning in Amarin Pharma, Inc. v. FDA, blocking the agency from pursuing a misbranding action against a company that wanted to promote its fish-oil drug for uses supported by clinical data. The court held that misbranding enforcement “based on truthful promotional speech alone” was not permitted under the First Amendment.
Those rulings did not legalize off-label promotion across the board. The protection reaches truthful, non-misleading, science-based speech. Promotional claims that are false, exaggerated, or unsupported by evidence remain fully prosecutable, and most of the big enforcement cases involve conduct that goes far beyond sharing accurate research: fabricated data, suppressed safety information, kickbacks, and campaigns designed to mislead. The First Amendment defense fits a narrow set of facts, and it is not the set most prosecuted companies present.
When Sharing Off-Label Information Is Allowed
The FDA has long recognized narrow situations where a manufacturer can communicate about an unapproved use without crossing into illegal promotion.
The most established one involves unsolicited requests. If a doctor independently asks a company for information about an off-label use, the company can respond with truthful, balanced, scientific information. The FDA issued draft guidance on this in 2011.7U.S. Food and Drug Administration. Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices The word “unsolicited” is doing real work. If a company engineers the question by priming doctors to ask, the safe harbor evaporates.
The FDA has separately issued guidance on firm-initiated communications of scientific information about unapproved uses to healthcare providers.8U.S. Food and Drug Administration. Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses And the FDCA itself carves out space for sharing “health care economic information” with insurers and formulary committees, as long as it is based on competent scientific evidence and relates to an approved indication.3Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices
None of these cover broad promotional campaigns aimed at driving off-label prescribing. They are narrow, context-specific channels for science-based communication. Companies that try to stretch them into a marketing strategy tend to become the next enforcement case.
What Enforcement Looks Like
The financial exposure in off-label cases is larger than most people expect. GlaxoSmithKline paid $3 billion in 2012 to resolve criminal and civil charges tied to promoting antidepressants for unapproved uses and failing to report safety data.9U.S. Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data Johnson & Johnson paid more than $2.2 billion in 2013 over off-label promotion of an antipsychotic. Abbott Labs paid $1.5 billion the year before over an epilepsy drug. Eli Lilly paid more than $1.4 billion between 2008 and 2010 over another antipsychotic. Those settlements are the pattern, not the outliers.
Fines are only part of it. Companies plead guilty to misbranding charges, and individual executives and sales managers have faced criminal prosecution, including prison. Settlements almost always include a Corporate Integrity Agreement with the HHS Office of Inspector General, typically running five years and requiring a compliance officer, independent external reviews, and hiring restrictions.10Office of Inspector General. Corporate Integrity Agreements Behind everything sits the threat of exclusion from Medicare, Medicaid, and other federal health programs, which for a large drugmaker functions as a corporate death sentence and is the main reason companies settle rather than fight.11Office of Inspector General. Exclusions Program
How Off-Label Cases Get Started
Most major off-label cases do not begin with an FDA or DOJ investigation. They begin with a whistleblower, usually a current or former employee who saw the conduct up close. The False Claims Act’s qui tam provisions let a private citizen file suit on the government’s behalf. The complaint is filed under seal while the DOJ investigates and decides whether to intervene. If the government joins the case, the whistleblower receives between 15 and 25 percent of the recovery. If the government declines and the whistleblower goes forward alone, the share rises to between 25 and 30 percent.12Office of the Law Revision Counsel. 31 USC 3730 – Civil Actions for False Claims
On a settlement the size of GlaxoSmithKline’s, even the low end of that range translates to hundreds of millions of dollars for the person who came forward. The incentive is a deliberate feature of the statute, and it drives the enforcement pipeline. Nearly every major pharmaceutical fraud settlement of the past two decades started with a qui tam complaint. If you work inside a company and are watching off-label promotion happen, that is the mechanism the law hands you.